Peer-reviewed veterinary case report
Anti-TGFB treatment tested for laryngotracheal stenosis in dogs
By Simpson, C Blake et al.·Published in The Laryngoscope·2008·Department of Otolaryngology-Head and Neck Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anti-transforming growth factor beta as a treatment for laryngotracheal stenosis in a canine model.
- Species:
- dog
Plain-English summary
A group of mixed-breed dogs developed laryngotracheal stenosis (narrowing of the airway) after a cautery injury to their throats. Four of the dogs received saline injections, while the other four were treated with a combination of intravenous and local injections of anti-transforming growth factor beta (anti-TGFB). The dogs treated with anti-TGFB showed less airway narrowing and lived longer compared to those that only received saline. This suggests that anti-TGFB could be a helpful treatment for this serious condition, but more research is needed to determine the best way to use it.
People also search for: dog laryngotracheal stenosis treatment · anti-TGFB for dogs · dog airway narrowing symptoms
Abstract
OBJECTIVES/HYPOTHESIS: Laryngotracheal stenosis (LTS) represents a significant treatment dilemma faced by otolaryngologists. Recent topical use of Mitomycin C as an adjunctive treatment has proved helpful but does not completely prevent stenosis. Current literature suggests that transforming growth factor beta (TGFB) plays a significant role in the development of subglottic stenosis. We modified an existing canine model to test antitransforming growth factor beta (anti-TGFB) as a possible treatment for laryngotracheal stenosis. STUDY DESIGN: Pilot study in a modified canine model. METHODS: Eight mixed-breed dogs underwent cautery injury to the subglottic region creating subsequent laryngotracheal stenosis. Four dogs were treated with saline injection into the injury site and four dogs were treated with a combination of intravenous (5 mg/kg on day 0 and 5 of the experiment) and local injection of anti-TGFB (50 micrograms). RESULTS: In the canine model of induced subglottic airway injury, a combination of intralesional and intravenous anti-TGFB results in a reduction in tracheal stenosis (P < .05) and an increase in survival time (P < .03) when compared to the saline control subjects. CONCLUSIONS: Anti-TGFB appears to be a useful adjunct in the treatment of LTS. Further study regarding the optimal dosing, route of administration, and timing of delivery is needed to understand the role of anti-TGFB in the treatment for laryngotracheal stenosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18176351/